Active substance
Etonogestrel
- SFDA 1
- US FDA 2
- Health Canada 1
- NHS prices 1
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| IMPLANON NXT IMPLANT 68MG | 68 mg | Implant · Subcutaneous use | 1 Implanter | SAR 444.85 | NCE · Prescription | ORGANON | Valid |
Indications — CHI Daman Drug Formulary
CONTRACEPTION; ENDOMETRIOSIS; MENSTRUAL DISORDERS
US FDA United States — FDA approvals (Drugs@FDA)
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| NEXPLANON | 02499509 | 68 MG | IMPLANT · SUBCUTANEOUS | ORGANON CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Etonogestrel 68mg implant | £83.43 | 1 device | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 9 Jul 2026 PRAC signal: Meningioma
Action for MAH: update of the product information: Yes - US FDA 28 May 2026 NEXPLANON — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Jan 2026 IMPLANON — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 27 Nov 2025 PRAC signal: Meningioma
Action for MAH: update of the product information: No - EMA PRAC 8 May 2025 PRAC signal: Meningioma
Action for MAH: update of the product information: No - US FDA 31 May 2024 NUVARING — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 10 Jan 2013 PRAC signal: Risk of arterial thrombotic event (ATE), thrombotic stroke and myocardial infarction
Action for MAH: update of the product information: No - EMA PRAC 29 Nov 2012 PRAC signal: Risk of arterial thrombotic event (ATE), thrombotic stroke and myocardial infarction
Action for MAH: update of the product information: No - EMA PRAC 3 Oct 2012 PRAC signal: Risk of arterial thrombotic event (ATE), thrombotic stroke and myocardial infarction
Action for MAH: update of the product information: No
Combinations containing Etonogestrel
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.